Are you Dr. Dumbrava?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 10 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Summary
- Dr. Ecaterina (Ileana) Dumbrava, MD is an oncologist in Houston, Texas. She is currently licensed to practice medicine in Texas, Florida, and Oklahoma. She is affiliated with University of Texas M.D. Anderson Cancer Center.
Education & Training
Iuliu Hatieganu University of Medicine and PharmacyClass of 2008
Certifications & Licensure
FL State Medical License 2024 - Present
TX State Medical License 2018 - 2025
OK State Medical License 2020 - 2021
Publications & Presentations
PubMed
- Human Epidermal Growth Factor Receptor 2 Loss Following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer.Mohamed A Gouda, Amrit Gonugunta, Ecaterina E Dumbrava, Timothy A Yap, Jordi Rodon
Clinical Cancer Research. 2025-01-22 - PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial.Mark N Stein, Ecaterina E Dumbrava, Benjamin A Teply, Usama S Gergis, Martin E Guiterrez
Nature Communications. 2024-12-30 - Sacituzumab Govitecan in Patients With Relapsed/Refractory Advanced Head and Neck Squamous Cell Carcinoma: Results From the Phase 2 TROPiCS-03 Basket Study.Loren Michel, Antonio Jimeno, Ammar Sukari, J Thaddeus Beck, Joanne Chiu
Clinical Cancer Research. 2024-12-12
Press Mentions
MD Anderson Research Highlights: SITC 2024 Special EditionNovember 9th, 2024- How Does Targeted Therapy Treat Cancer?June 7th, 2024
- Compugen Presents Preliminary Results from Phase 1/2 Dose Escalation Study of COM701 with Opdivo® and BMS-986207 (Anti-TIGIT Antibody) at SITC 2021November 12th, 2021
